BDRX (Biodexa Pharmaceuticals) EBIT per Share: $-109.24 (TTM As of Dec. 2025)

What is Biodexa Pharmaceuticals EBIT per Share?

Biodexa Pharmaceuticals BDRX -2.00% 24 EBIT per Share is $-109.24 as of Dec. 2025. GuruFocus rates BDRX with a GF Score™ of 24/100. Among 1,174 Biotechnology companies, Biodexa Pharmaceuticals ranks worse than 85178.79% on this metric.

Biodexa Pharmaceuticals's EBIT per Share for the six months ended in Dec. 2025 was $-7.18. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-109.24.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Biodexa Pharmaceuticals's EBIT per Share or its related term are showing as below:

BDRX's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 15.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Biodexa Pharmaceuticals's EBIT for the six months ended in Dec. 2025 was $-3.25 Mil.

Biodexa Pharmaceuticals (NAS:BDRX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Biodexa Pharmaceuticals EBIT per Share Related Terms

Biodexa Pharmaceuticals EBIT per Share Historical Data

* Premium members only.

The historical data trend for Biodexa Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biodexa Pharmaceuticals EBIT per Share Chart

Biodexa Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT per Share

Get a 7-Day Free Trial

0.00

-3,675.00

-380.91

Biodexa Pharmaceuticals Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
EBIT per Share	Get a 7-Day Free Trial															-2,285.00	-615.00	-236.31	-102.06	-7.18

24GF Score

Biodexa Pharmaceuticals PLC BDRX

EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Biodexa Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Biodexa Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

	EBIT per Share		(A: Dec. 2025 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-8.38	/	0.022
=	-380.91

Biodexa Pharmaceuticals's EBIT per Share for the quarter that ended in Dec. 2025 is calculated as

	EBIT per Share		(Q: Dec. 2025 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-3.245	/	0.452
=	-7.18

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-109.24

Frequently Asked Questions Learn more about EBIT per Share →

What does a EBIT per Share of $-109.24 mean?

Biodexa Pharmaceuticals (BDRX) has a EBIT per Share of $-109.24 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Biodexa Pharmaceuticals and its competitors. According to the industry distribution chart, Biodexa Pharmaceuticals ranks #999999 out of 1174 companies in the Biotechnology industry.

Is Biodexa Pharmaceuticals' EBIT per Share too high?

Biodexa Pharmaceuticals' current EBIT per Share is $-109.24. Based on the distribution chart, Biodexa Pharmaceuticals ranks #999999 out of 1174 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biodexa Pharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.

How does Biodexa Pharmaceuticals' EBIT per Share compare to ADTX and AAGH?

According to the Biotechnology industry distribution chart, Biodexa Pharmaceuticals ranks #999999 out of 1174 companies for EBIT per Share. This places Biodexa Pharmaceuticals in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT per Share for a Biotechnology company?

The median EBIT per Share among Biotechnology companies is 15.40, based on 1,174 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT per Share mean?

A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Biodexa Pharmaceuticals and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biodexa Pharmaceuticals's current EBIT per Share is $-109.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Biodexa Pharmaceuticals stock overvalued right now?

Biodexa Pharmaceuticals (BDRX) has a current EBIT per Share of $-109.24. The current EBIT per Share is $-109.24. Biodexa Pharmaceuticals' overall GF Score™ is 24/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT per Share calculated?

EBIT per Share is calculated from a company's financial statements. For Biodexa Pharmaceuticals (BDRX), the current EBIT per Share is $-109.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biodexa Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies ADTX AAGH PKTX VBIO BBLG BPTH VRAX HEPA AXIM OGEN VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ

Website https://www.biodexapharma.com

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.

24GF Score

Get the complete analysis for BDRX

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.94

Price

View BDRX Analysis

See EBIT per Share data for all stocks →